Shrimp Disease Diagnostics Market

In this report, the Shrimps Disease Diagnostics Market has been segmented by Disease Type, Kits, End User, and Geography.

Shrimps Disease Diagnostics Market, Segmentation by Disease Type

The Shrimps Disease Diagnostics Market has been segmented by Disease Type into WSSV (White Spot Syndrome Virus), TSV (Taura Syndrome Virus), YHV/GAV (Yellow Head/Gill Associated Virus), IHHNV (Infectious Hypodermal and Hematopoietic Virus), HPV (Hepatopancreatic Parvovirus), MBV (Monodon Baculovirus), IMNV (Infectious Myonecrosis Virus), NHP-B (Necrotising Hepatopancreatitis Bacteria), MoV (Mourilyan Virus), and Early Mortality Syndrome (EMS)

WSSV (White Spot Syndrome Virus)
WSSV leads the Shrimps Disease Diagnostics Market with a share of approximately 30%. This highly virulent disease causes rapid mortality in shrimp populations, making early detection and real-time diagnostics crucial for outbreak prevention and biosecurity management in aquaculture farms.

TSV (Taura Syndrome Virus)
TSV accounts for nearly 15% of the market. This virus primarily affects Penaeus vannamei and causes lethargy, anorexia, and high mortality rates. Accurate molecular testing is essential for prompt diagnosis and reducing economic losses in shrimp farming operations.

YHV/GAV (Yellow Head/Gill Associated Virus)
YHV/GAV contributes about 10% to the market. These viruses lead to gill discoloration, hepatopancreas dysfunction, and mass die-offs. The demand for sensitive PCR-based assays has increased to detect infections early and prevent transmission in intensive farming systems.

IHHNV (Infectious Hypodermal and Hematopoietic Virus)
IHHNV holds around 8% of the diagnostics market. Though less fatal, it causes growth retardation and deformities in shrimp, affecting market value. Continuous screening using DNA probes and RT-PCR techniques is helping mitigate its economic impact.

HPV (Hepatopancreatic Parvovirus)
HPV represents approximately 6% of the market. It compromises digestive efficiency and weakens immunity in shrimp. The use of quantitative PCR diagnostics is gaining momentum to ensure accurate detection, especially in larval stages.

MBV (Monodon Baculovirus)
MBV makes up close to 5% of the market. It primarily affects Penaeus monodon juveniles, leading to reduced survival rates. The adoption of histopathological screening and targeted molecular diagnostics supports improved health monitoring in hatcheries.

IMNV (Infectious Myonecrosis Virus)
IMNV contributes around 7% to the market. It causes muscle necrosis and reduced motility in shrimp. Real-time diagnostics and routine surveillance programs are being implemented to manage outbreaks, especially in Latin American regions.

NHP-B (Necrotising Hepatopancreatitis Bacteria)
NHP-B holds about 6% of the market and is a bacterial disease causing severe liver damage and high mortality. Its diagnosis involves bacterial culture, histopathology, and PCR assays, critical for effective treatment and antibiotic management.

MoV (Mourilyan Virus)
MoV represents approximately 2% of the market. Though less common, its impact on growth performance in shrimp makes detection important. Advanced molecular diagnostics are under development to improve surveillance and early intervention strategies.

Early Mortality Syndrome (EMS)
EMS contributes nearly 11% of the market. Characterized by mass die-offs within the first 30 days of stocking, EMS is linked to vibrio-related infections. Rapid diagnostics such as loop-mediated isothermal amplification (LAMP) and qPCR are being widely adopted to minimize losses.

Shrimps Disease Diagnostics Market, Segmentation by Kits

The Shrimps Disease Diagnostics Market has been segmented by Kits into Assay Based Kits, and Rapid Testing Kits

Assay Based Kits
Assay Based Kits dominate the Shrimps Disease Diagnostics Market with a share of approximately 65%. These kits include PCR, ELISA, and qPCR-based solutions that offer high sensitivity and specificity in detecting a wide range of viral and bacterial pathogens. Their accuracy and compatibility with lab-based screening make them a preferred choice for commercial aquaculture facilities and research labs.

Rapid Testing Kits
Rapid Testing Kits account for nearly 35% of the market and are increasingly used for on-site diagnostics. These kits offer quick results with minimal equipment, enabling shrimp farmers to conduct real-time disease surveillance and make immediate biosecurity decisions. Their portability and cost-effectiveness are key factors driving adoption, especially in remote and small-scale operations.

Shrimps Disease Diagnostics Market, Segmentation by End User

The Shrimps Disease Diagnostics Market has been segmented by End User into Fisheries, Aquaculture Laboratories, Marine Laboratories, Education, and Research Institutes, and Others.

Fisheries
Fisheries constitute the largest share of the Shrimps Disease Diagnostics Market, accounting for approximately 38%. These end users rely heavily on rapid disease detection kits and routine health screening to minimize losses from viral and bacterial outbreaks. Ensuring stock quality and market compliance are critical for their operational efficiency.

Aquaculture Laboratories
Aquaculture Laboratories hold about 28% of the market. These labs serve as diagnostic hubs, offering PCR assays, histopathological analysis, and advanced pathogen surveillance. Their role in high-throughput testing and supporting large-scale farms makes them vital to maintaining aquaculture health standards.

Marine Laboratories
Marine Laboratories contribute nearly 14% of the market. Focused on coastal monitoring and ecosystem management, they utilize shrimp diagnostics to track disease outbreaks in wild populations and assess environmental health risks. This supports both conservation efforts and policy planning.

Education and Research Institutes
Education and Research Institutes represent about 12% of the market. These institutions conduct epidemiological studies, test new diagnostic tools, and develop disease management protocols. Their contributions are essential for advancing the scientific understanding of shrimp pathology and improving future diagnostic technologies.

Others
The 'Others' segment holds approximately 8% of the market and includes private consultants, government health agencies, and export inspection bodies. Their involvement in certification processes and biosecurity audits plays a key role in upholding shrimp health regulations across global trade routes.

Shrimps Disease Diagnostics Market, Segmentation by Geography

In this report, the Shrimps Disease Diagnostics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East, and Africa, and Latin America.

Shrimps Disease Diagnostics Market Share (%), by Geographical Region

North America
North America holds approximately 22% of the Shrimps Disease Diagnostics Market. The region benefits from advanced aquaculture practices, high regulatory standards, and strong presence of diagnostic technology providers. The U.S. and Canada continue to invest in biosecurity protocols and early detection systems to prevent disease outbreaks.

Europe
Europe contributes nearly 18% of the market, driven by increasing demand for sustainable seafood production and robust marine disease surveillance programs. Countries like Norway, Spain, and the Netherlands are adopting molecular diagnostic tools to support shrimp health management and reduce dependency on antibiotic treatments.

Asia Pacific
Asia Pacific dominates the global market with a share of around 42%. As the world’s largest shrimp-producing region, countries such as China, India, Vietnam, and Thailand rely heavily on rapid testing and assay-based diagnostics to control viral and bacterial outbreaks. Government initiatives promoting aquaculture biosecurity are also boosting market growth.

Middle East and Africa
Middle East and Africa account for roughly 10% of the market. The region is gradually expanding its aquaculture capacity, with increasing attention toward preventive health measures. Countries like Egypt and South Africa are introducing modern diagnostic labs to support shrimp farming efficiency.

Latin America
Latin America represents around 8% of the Shrimps Disease Diagnostics Market. Nations such as Brazil, Ecuador, and Mexico are actively investing in diagnostic infrastructure to manage early mortality syndrome (EMS) and other viral threats. Growing export demand is pushing the need for stringent disease control systems.

This report provides an in depth analysis of various factors that impact the dynamics of Global Shrimps Disease Diagnostics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Key players in Global Shrimps Disease Diagnostics Market include:

• Sdn Bhd
• REAGEN LLC
• FUJIKURA KASEI CO., LTD.,
• GeneReach Biotechnology Corp.
• Thermo Fisher Scientific
• Lab - Ind Resource Sdn Bhd.
• AquaBounty Technologies, Inc

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis